Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia - Trial NCT06285890
Access comprehensive clinical trial information for NCT06285890 through Pure Global AI's free database. This Phase 1 trial is sponsored by M.D. Anderson Cancer Center and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 18 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
M.D. Anderson Cancer Center
Timeline & Enrollment
Phase 1
Aug 31, 2024
Dec 31, 2029
Primary Outcome
Safety and adverse events (AEs)
Summary
To find a recommended dose of HC-7366 that can be given in combination with azacitidine and
 venetoclax to patients with AML. The safety and effects of this drug combination will also be
 studied.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06285890
Non-Device Trial